Loading…
Protection from diabetes-induced atherosclerosis and renal disease by d-carnosine-octylester: effects of early vs late inhibition of advanced glycation end-products in Apoe-null mice
Aims/hypothesis AGEs are involved in diabetic complications and might be responsible for the phenomenon of ‘hyperglycaemic memory’. d -Carnosine-octylester (DCO) has been shown to attenuate AGE formation and vascular and renal injury induced by high-fat diet in Apoe -null mice. This study aimed to v...
Saved in:
Published in: | Diabetologia 2015-04, Vol.58 (4), p.845-853 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c485t-7f146e1a78f9baa3ec8ccf553e63f3c218beacc18fd2483fdf748cfaaec268523 |
---|---|
cites | cdi_FETCH-LOGICAL-c485t-7f146e1a78f9baa3ec8ccf553e63f3c218beacc18fd2483fdf748cfaaec268523 |
container_end_page | 853 |
container_issue | 4 |
container_start_page | 845 |
container_title | Diabetologia |
container_volume | 58 |
creator | Menini, Stefano Iacobini, Carla Ricci, Carlo Fantauzzi, Claudia Blasetti Pugliese, Giuseppe |
description | Aims/hypothesis
AGEs are involved in diabetic complications and might be responsible for the phenomenon of ‘hyperglycaemic memory’.
d
-Carnosine-octylester (DCO) has been shown to attenuate AGE formation and vascular and renal injury induced by high-fat diet in
Apoe
-null mice. This study aimed to verify the protective effect of DCO in atherosclerosis and renal disease induced by experimental diabetes and to discover whether reduction of AGE formation by early vs late DCO treatment provides better macro and microvascular protection.
Methods
Apoe
-null mice were rendered diabetic by streptozotocin and were left untreated or were treated with DCO for 20 weeks (DCO-Extended), from week 1 to 11 (DCO-Early) or from week 9 to 19 (DCO-Late). Non-diabetic
Apoe
-null mice served as controls. Aortic and renal lesions were evaluated by morphometry and protein and gene expression of disease markers were assessed by immunohistochemistry and real-time PCR.
Results
DCO-Extended treatment produced a more stable plaque phenotype by markedly attenuating diabetes-induced increases in lesion size, necrotic core area and plaque content of Nε-carboxymethyllysine, levels of apoptotic cells and markers of inflammation and oxidative stress and also reductions in collagen and smooth muscle cells. DCO treatment for 11 weeks afforded partial protection and this was significantly better in DCO-Early mice than in DCO-Late mice. Renal disease was attenuated in DCO-Extended mice and to a lesser extent in those treated for 11 weeks, with no significant difference between DCO-Early mice and DCO-Late mice.
Conclusions/interpretation
These data show that DCO protects mice from diabetes-induced vascular and renal disease and that protection against atherosclerosis is more effectively achieved by early treatment than by late treatment, thus suggesting that early inhibition of AGE formation attenuates progression of macroangiopathy and favours development of more stable lesions. |
doi_str_mv | 10.1007/s00125-014-3467-6 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1661330914</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1661330914</sourcerecordid><originalsourceid>FETCH-LOGICAL-c485t-7f146e1a78f9baa3ec8ccf553e63f3c218beacc18fd2483fdf748cfaaec268523</originalsourceid><addsrcrecordid>eNp1kcGKFDEQhoMo7uzoA3iRgBcv0aSTTme8LYu6woIeFLw11UllN0smPSbdC_1iPp_pmVVE8JJA_q_-qtRPyAvB3wjOu7eFc9G0jAvFpNId04_IRijZMK4a85hsVpkJo7-fkfNS7jjnslX6KTlrWtWJbqc25OeXPE5opzAm6vO4py7AgBMWFpKbLToK0y3msdi4nqFQSI5mTBArWhAK0mGhjlnIqeoJ2WinJWKZML-j6H01L3T0FCHHhd4XGmFCGtJtGMKxbdXA3UNam93ExcLxFZNjhzzWGWp5SPTiMCJLc4x0Hyw-I088xILPH-4t-fbh_dfLK3b9-eOny4trZpVpJ9Z5oTQK6IzfDQASrbHWt61ELb20jTADgrXCeNcoI73znTLWA6BttGkbuSWvT751lB9z_VS_D8VijJBwnEsvtBZS8l3d-pa8-ge9G-dc93SkuDFadaZS4kTZus2S0feHHPaQl17wfg21P4Xa11D7NdRe15qXD87zsEf3p-J3ihVoTkCpUrrB_Ffr_7r-AoYAsbM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1660886478</pqid></control><display><type>article</type><title>Protection from diabetes-induced atherosclerosis and renal disease by d-carnosine-octylester: effects of early vs late inhibition of advanced glycation end-products in Apoe-null mice</title><source>Springer Nature</source><creator>Menini, Stefano ; Iacobini, Carla ; Ricci, Carlo ; Fantauzzi, Claudia Blasetti ; Pugliese, Giuseppe</creator><creatorcontrib>Menini, Stefano ; Iacobini, Carla ; Ricci, Carlo ; Fantauzzi, Claudia Blasetti ; Pugliese, Giuseppe</creatorcontrib><description>Aims/hypothesis
AGEs are involved in diabetic complications and might be responsible for the phenomenon of ‘hyperglycaemic memory’.
d
-Carnosine-octylester (DCO) has been shown to attenuate AGE formation and vascular and renal injury induced by high-fat diet in
Apoe
-null mice. This study aimed to verify the protective effect of DCO in atherosclerosis and renal disease induced by experimental diabetes and to discover whether reduction of AGE formation by early vs late DCO treatment provides better macro and microvascular protection.
Methods
Apoe
-null mice were rendered diabetic by streptozotocin and were left untreated or were treated with DCO for 20 weeks (DCO-Extended), from week 1 to 11 (DCO-Early) or from week 9 to 19 (DCO-Late). Non-diabetic
Apoe
-null mice served as controls. Aortic and renal lesions were evaluated by morphometry and protein and gene expression of disease markers were assessed by immunohistochemistry and real-time PCR.
Results
DCO-Extended treatment produced a more stable plaque phenotype by markedly attenuating diabetes-induced increases in lesion size, necrotic core area and plaque content of Nε-carboxymethyllysine, levels of apoptotic cells and markers of inflammation and oxidative stress and also reductions in collagen and smooth muscle cells. DCO treatment for 11 weeks afforded partial protection and this was significantly better in DCO-Early mice than in DCO-Late mice. Renal disease was attenuated in DCO-Extended mice and to a lesser extent in those treated for 11 weeks, with no significant difference between DCO-Early mice and DCO-Late mice.
Conclusions/interpretation
These data show that DCO protects mice from diabetes-induced vascular and renal disease and that protection against atherosclerosis is more effectively achieved by early treatment than by late treatment, thus suggesting that early inhibition of AGE formation attenuates progression of macroangiopathy and favours development of more stable lesions.</description><identifier>ISSN: 0012-186X</identifier><identifier>EISSN: 1432-0428</identifier><identifier>DOI: 10.1007/s00125-014-3467-6</identifier><identifier>PMID: 25471794</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject><![CDATA[Age ; Animals ; Aorta - drug effects ; Aorta - metabolism ; Aorta - pathology ; Aortic Diseases - blood ; Aortic Diseases - diagnosis ; Aortic Diseases - genetics ; Aortic Diseases - prevention & control ; Apolipoproteins E - deficiency ; Apolipoproteins E - genetics ; Atherosclerosis ; Atherosclerosis - blood ; Atherosclerosis - diagnosis ; Atherosclerosis - genetics ; Atherosclerosis - prevention & control ; Biomarkers - blood ; Carnosine - analogs & derivatives ; Carnosine - pharmacology ; Diabetes ; Diabetes Mellitus, Experimental - blood ; Diabetes Mellitus, Experimental - diagnosis ; Diabetes Mellitus, Experimental - drug therapy ; Diabetes Mellitus, Experimental - genetics ; Diabetic Angiopathies - blood ; Diabetic Angiopathies - diagnosis ; Diabetic Angiopathies - genetics ; Diabetic Angiopathies - prevention & control ; Diabetic Nephropathies - blood ; Diabetic Nephropathies - diagnosis ; Diabetic Nephropathies - genetics ; Diabetic Nephropathies - prevention & control ; Disease Progression ; Epidemiology ; Female ; Glycation End Products, Advanced - antagonists & inhibitors ; Glycation End Products, Advanced - blood ; Human Physiology ; Hyperglycemia ; Internal Medicine ; Kidney - drug effects ; Kidney - metabolism ; Kidney - pathology ; Kidney diseases ; Laboratory animals ; Medicine ; Medicine & Public Health ; Metabolic Diseases ; Metabolism ; Mice ; Mice, Knockout ; Plaque, Atherosclerotic ; Signal Transduction - drug effects ; Smooth muscle ; Time Factors]]></subject><ispartof>Diabetologia, 2015-04, Vol.58 (4), p.845-853</ispartof><rights>Springer-Verlag Berlin Heidelberg 2014</rights><rights>Springer-Verlag Berlin Heidelberg 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c485t-7f146e1a78f9baa3ec8ccf553e63f3c218beacc18fd2483fdf748cfaaec268523</citedby><cites>FETCH-LOGICAL-c485t-7f146e1a78f9baa3ec8ccf553e63f3c218beacc18fd2483fdf748cfaaec268523</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25471794$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Menini, Stefano</creatorcontrib><creatorcontrib>Iacobini, Carla</creatorcontrib><creatorcontrib>Ricci, Carlo</creatorcontrib><creatorcontrib>Fantauzzi, Claudia Blasetti</creatorcontrib><creatorcontrib>Pugliese, Giuseppe</creatorcontrib><title>Protection from diabetes-induced atherosclerosis and renal disease by d-carnosine-octylester: effects of early vs late inhibition of advanced glycation end-products in Apoe-null mice</title><title>Diabetologia</title><addtitle>Diabetologia</addtitle><addtitle>Diabetologia</addtitle><description>Aims/hypothesis
AGEs are involved in diabetic complications and might be responsible for the phenomenon of ‘hyperglycaemic memory’.
d
-Carnosine-octylester (DCO) has been shown to attenuate AGE formation and vascular and renal injury induced by high-fat diet in
Apoe
-null mice. This study aimed to verify the protective effect of DCO in atherosclerosis and renal disease induced by experimental diabetes and to discover whether reduction of AGE formation by early vs late DCO treatment provides better macro and microvascular protection.
Methods
Apoe
-null mice were rendered diabetic by streptozotocin and were left untreated or were treated with DCO for 20 weeks (DCO-Extended), from week 1 to 11 (DCO-Early) or from week 9 to 19 (DCO-Late). Non-diabetic
Apoe
-null mice served as controls. Aortic and renal lesions were evaluated by morphometry and protein and gene expression of disease markers were assessed by immunohistochemistry and real-time PCR.
Results
DCO-Extended treatment produced a more stable plaque phenotype by markedly attenuating diabetes-induced increases in lesion size, necrotic core area and plaque content of Nε-carboxymethyllysine, levels of apoptotic cells and markers of inflammation and oxidative stress and also reductions in collagen and smooth muscle cells. DCO treatment for 11 weeks afforded partial protection and this was significantly better in DCO-Early mice than in DCO-Late mice. Renal disease was attenuated in DCO-Extended mice and to a lesser extent in those treated for 11 weeks, with no significant difference between DCO-Early mice and DCO-Late mice.
Conclusions/interpretation
These data show that DCO protects mice from diabetes-induced vascular and renal disease and that protection against atherosclerosis is more effectively achieved by early treatment than by late treatment, thus suggesting that early inhibition of AGE formation attenuates progression of macroangiopathy and favours development of more stable lesions.</description><subject>Age</subject><subject>Animals</subject><subject>Aorta - drug effects</subject><subject>Aorta - metabolism</subject><subject>Aorta - pathology</subject><subject>Aortic Diseases - blood</subject><subject>Aortic Diseases - diagnosis</subject><subject>Aortic Diseases - genetics</subject><subject>Aortic Diseases - prevention & control</subject><subject>Apolipoproteins E - deficiency</subject><subject>Apolipoproteins E - genetics</subject><subject>Atherosclerosis</subject><subject>Atherosclerosis - blood</subject><subject>Atherosclerosis - diagnosis</subject><subject>Atherosclerosis - genetics</subject><subject>Atherosclerosis - prevention & control</subject><subject>Biomarkers - blood</subject><subject>Carnosine - analogs & derivatives</subject><subject>Carnosine - pharmacology</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Experimental - blood</subject><subject>Diabetes Mellitus, Experimental - diagnosis</subject><subject>Diabetes Mellitus, Experimental - drug therapy</subject><subject>Diabetes Mellitus, Experimental - genetics</subject><subject>Diabetic Angiopathies - blood</subject><subject>Diabetic Angiopathies - diagnosis</subject><subject>Diabetic Angiopathies - genetics</subject><subject>Diabetic Angiopathies - prevention & control</subject><subject>Diabetic Nephropathies - blood</subject><subject>Diabetic Nephropathies - diagnosis</subject><subject>Diabetic Nephropathies - genetics</subject><subject>Diabetic Nephropathies - prevention & control</subject><subject>Disease Progression</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Glycation End Products, Advanced - antagonists & inhibitors</subject><subject>Glycation End Products, Advanced - blood</subject><subject>Human Physiology</subject><subject>Hyperglycemia</subject><subject>Internal Medicine</subject><subject>Kidney - drug effects</subject><subject>Kidney - metabolism</subject><subject>Kidney - pathology</subject><subject>Kidney diseases</subject><subject>Laboratory animals</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolic Diseases</subject><subject>Metabolism</subject><subject>Mice</subject><subject>Mice, Knockout</subject><subject>Plaque, Atherosclerotic</subject><subject>Signal Transduction - drug effects</subject><subject>Smooth muscle</subject><subject>Time Factors</subject><issn>0012-186X</issn><issn>1432-0428</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp1kcGKFDEQhoMo7uzoA3iRgBcv0aSTTme8LYu6woIeFLw11UllN0smPSbdC_1iPp_pmVVE8JJA_q_-qtRPyAvB3wjOu7eFc9G0jAvFpNId04_IRijZMK4a85hsVpkJo7-fkfNS7jjnslX6KTlrWtWJbqc25OeXPE5opzAm6vO4py7AgBMWFpKbLToK0y3msdi4nqFQSI5mTBArWhAK0mGhjlnIqeoJ2WinJWKZML-j6H01L3T0FCHHhd4XGmFCGtJtGMKxbdXA3UNam93ExcLxFZNjhzzWGWp5SPTiMCJLc4x0Hyw-I088xILPH-4t-fbh_dfLK3b9-eOny4trZpVpJ9Z5oTQK6IzfDQASrbHWt61ELb20jTADgrXCeNcoI73znTLWA6BttGkbuSWvT751lB9z_VS_D8VijJBwnEsvtBZS8l3d-pa8-ge9G-dc93SkuDFadaZS4kTZus2S0feHHPaQl17wfg21P4Xa11D7NdRe15qXD87zsEf3p-J3ihVoTkCpUrrB_Ffr_7r-AoYAsbM</recordid><startdate>20150401</startdate><enddate>20150401</enddate><creator>Menini, Stefano</creator><creator>Iacobini, Carla</creator><creator>Ricci, Carlo</creator><creator>Fantauzzi, Claudia Blasetti</creator><creator>Pugliese, Giuseppe</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20150401</creationdate><title>Protection from diabetes-induced atherosclerosis and renal disease by d-carnosine-octylester: effects of early vs late inhibition of advanced glycation end-products in Apoe-null mice</title><author>Menini, Stefano ; Iacobini, Carla ; Ricci, Carlo ; Fantauzzi, Claudia Blasetti ; Pugliese, Giuseppe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c485t-7f146e1a78f9baa3ec8ccf553e63f3c218beacc18fd2483fdf748cfaaec268523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Age</topic><topic>Animals</topic><topic>Aorta - drug effects</topic><topic>Aorta - metabolism</topic><topic>Aorta - pathology</topic><topic>Aortic Diseases - blood</topic><topic>Aortic Diseases - diagnosis</topic><topic>Aortic Diseases - genetics</topic><topic>Aortic Diseases - prevention & control</topic><topic>Apolipoproteins E - deficiency</topic><topic>Apolipoproteins E - genetics</topic><topic>Atherosclerosis</topic><topic>Atherosclerosis - blood</topic><topic>Atherosclerosis - diagnosis</topic><topic>Atherosclerosis - genetics</topic><topic>Atherosclerosis - prevention & control</topic><topic>Biomarkers - blood</topic><topic>Carnosine - analogs & derivatives</topic><topic>Carnosine - pharmacology</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Experimental - blood</topic><topic>Diabetes Mellitus, Experimental - diagnosis</topic><topic>Diabetes Mellitus, Experimental - drug therapy</topic><topic>Diabetes Mellitus, Experimental - genetics</topic><topic>Diabetic Angiopathies - blood</topic><topic>Diabetic Angiopathies - diagnosis</topic><topic>Diabetic Angiopathies - genetics</topic><topic>Diabetic Angiopathies - prevention & control</topic><topic>Diabetic Nephropathies - blood</topic><topic>Diabetic Nephropathies - diagnosis</topic><topic>Diabetic Nephropathies - genetics</topic><topic>Diabetic Nephropathies - prevention & control</topic><topic>Disease Progression</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Glycation End Products, Advanced - antagonists & inhibitors</topic><topic>Glycation End Products, Advanced - blood</topic><topic>Human Physiology</topic><topic>Hyperglycemia</topic><topic>Internal Medicine</topic><topic>Kidney - drug effects</topic><topic>Kidney - metabolism</topic><topic>Kidney - pathology</topic><topic>Kidney diseases</topic><topic>Laboratory animals</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolic Diseases</topic><topic>Metabolism</topic><topic>Mice</topic><topic>Mice, Knockout</topic><topic>Plaque, Atherosclerotic</topic><topic>Signal Transduction - drug effects</topic><topic>Smooth muscle</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Menini, Stefano</creatorcontrib><creatorcontrib>Iacobini, Carla</creatorcontrib><creatorcontrib>Ricci, Carlo</creatorcontrib><creatorcontrib>Fantauzzi, Claudia Blasetti</creatorcontrib><creatorcontrib>Pugliese, Giuseppe</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database (Proquest)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetologia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Menini, Stefano</au><au>Iacobini, Carla</au><au>Ricci, Carlo</au><au>Fantauzzi, Claudia Blasetti</au><au>Pugliese, Giuseppe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Protection from diabetes-induced atherosclerosis and renal disease by d-carnosine-octylester: effects of early vs late inhibition of advanced glycation end-products in Apoe-null mice</atitle><jtitle>Diabetologia</jtitle><stitle>Diabetologia</stitle><addtitle>Diabetologia</addtitle><date>2015-04-01</date><risdate>2015</risdate><volume>58</volume><issue>4</issue><spage>845</spage><epage>853</epage><pages>845-853</pages><issn>0012-186X</issn><eissn>1432-0428</eissn><abstract>Aims/hypothesis
AGEs are involved in diabetic complications and might be responsible for the phenomenon of ‘hyperglycaemic memory’.
d
-Carnosine-octylester (DCO) has been shown to attenuate AGE formation and vascular and renal injury induced by high-fat diet in
Apoe
-null mice. This study aimed to verify the protective effect of DCO in atherosclerosis and renal disease induced by experimental diabetes and to discover whether reduction of AGE formation by early vs late DCO treatment provides better macro and microvascular protection.
Methods
Apoe
-null mice were rendered diabetic by streptozotocin and were left untreated or were treated with DCO for 20 weeks (DCO-Extended), from week 1 to 11 (DCO-Early) or from week 9 to 19 (DCO-Late). Non-diabetic
Apoe
-null mice served as controls. Aortic and renal lesions were evaluated by morphometry and protein and gene expression of disease markers were assessed by immunohistochemistry and real-time PCR.
Results
DCO-Extended treatment produced a more stable plaque phenotype by markedly attenuating diabetes-induced increases in lesion size, necrotic core area and plaque content of Nε-carboxymethyllysine, levels of apoptotic cells and markers of inflammation and oxidative stress and also reductions in collagen and smooth muscle cells. DCO treatment for 11 weeks afforded partial protection and this was significantly better in DCO-Early mice than in DCO-Late mice. Renal disease was attenuated in DCO-Extended mice and to a lesser extent in those treated for 11 weeks, with no significant difference between DCO-Early mice and DCO-Late mice.
Conclusions/interpretation
These data show that DCO protects mice from diabetes-induced vascular and renal disease and that protection against atherosclerosis is more effectively achieved by early treatment than by late treatment, thus suggesting that early inhibition of AGE formation attenuates progression of macroangiopathy and favours development of more stable lesions.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>25471794</pmid><doi>10.1007/s00125-014-3467-6</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0012-186X |
ispartof | Diabetologia, 2015-04, Vol.58 (4), p.845-853 |
issn | 0012-186X 1432-0428 |
language | eng |
recordid | cdi_proquest_miscellaneous_1661330914 |
source | Springer Nature |
subjects | Age Animals Aorta - drug effects Aorta - metabolism Aorta - pathology Aortic Diseases - blood Aortic Diseases - diagnosis Aortic Diseases - genetics Aortic Diseases - prevention & control Apolipoproteins E - deficiency Apolipoproteins E - genetics Atherosclerosis Atherosclerosis - blood Atherosclerosis - diagnosis Atherosclerosis - genetics Atherosclerosis - prevention & control Biomarkers - blood Carnosine - analogs & derivatives Carnosine - pharmacology Diabetes Diabetes Mellitus, Experimental - blood Diabetes Mellitus, Experimental - diagnosis Diabetes Mellitus, Experimental - drug therapy Diabetes Mellitus, Experimental - genetics Diabetic Angiopathies - blood Diabetic Angiopathies - diagnosis Diabetic Angiopathies - genetics Diabetic Angiopathies - prevention & control Diabetic Nephropathies - blood Diabetic Nephropathies - diagnosis Diabetic Nephropathies - genetics Diabetic Nephropathies - prevention & control Disease Progression Epidemiology Female Glycation End Products, Advanced - antagonists & inhibitors Glycation End Products, Advanced - blood Human Physiology Hyperglycemia Internal Medicine Kidney - drug effects Kidney - metabolism Kidney - pathology Kidney diseases Laboratory animals Medicine Medicine & Public Health Metabolic Diseases Metabolism Mice Mice, Knockout Plaque, Atherosclerotic Signal Transduction - drug effects Smooth muscle Time Factors |
title | Protection from diabetes-induced atherosclerosis and renal disease by d-carnosine-octylester: effects of early vs late inhibition of advanced glycation end-products in Apoe-null mice |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T04%3A48%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Protection%20from%20diabetes-induced%20atherosclerosis%20and%20renal%20disease%20by%20d-carnosine-octylester:%20effects%20of%20early%20vs%20late%20inhibition%20of%20advanced%20glycation%20end-products%20in%20Apoe-null%20mice&rft.jtitle=Diabetologia&rft.au=Menini,%20Stefano&rft.date=2015-04-01&rft.volume=58&rft.issue=4&rft.spage=845&rft.epage=853&rft.pages=845-853&rft.issn=0012-186X&rft.eissn=1432-0428&rft_id=info:doi/10.1007/s00125-014-3467-6&rft_dat=%3Cproquest_cross%3E1661330914%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c485t-7f146e1a78f9baa3ec8ccf553e63f3c218beacc18fd2483fdf748cfaaec268523%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1660886478&rft_id=info:pmid/25471794&rfr_iscdi=true |